AR039846A1 - Molecula de acido nucleico que codifica un antigeno de muc-1, siendo dicha molecula capaz de producir una respuesta inmune in vivo - Google Patents
Molecula de acido nucleico que codifica un antigeno de muc-1, siendo dicha molecula capaz de producir una respuesta inmune in vivoInfo
- Publication number
- AR039846A1 AR039846A1 ARP030101782A ARP030101782A AR039846A1 AR 039846 A1 AR039846 A1 AR 039846A1 AR P030101782 A ARP030101782 A AR P030101782A AR P030101782 A ARP030101782 A AR P030101782A AR 039846 A1 AR039846 A1 AR 039846A1
- Authority
- AR
- Argentina
- Prior art keywords
- nucleic acid
- molecula
- muc
- codifying
- vivo
- Prior art date
Links
- 102000039446 nucleic acids Human genes 0.000 title abstract 5
- 108020004707 nucleic acids Proteins 0.000 title abstract 5
- 150000007523 nucleic acids Chemical class 0.000 title abstract 5
- 102100034256 Mucin-1 Human genes 0.000 title abstract 3
- 108010008707 Mucin-1 Proteins 0.000 title abstract 3
- 230000028993 immune response Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0212046.7A GB0212046D0 (en) | 2002-05-24 | 2002-05-24 | Vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039846A1 true AR039846A1 (es) | 2005-03-02 |
Family
ID=9937394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101782A AR039846A1 (es) | 2002-05-24 | 2003-05-22 | Molecula de acido nucleico que codifica un antigeno de muc-1, siendo dicha molecula capaz de producir una respuesta inmune in vivo |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20060251665A1 (enExample) |
| EP (1) | EP1527177A2 (enExample) |
| JP (1) | JP2005526520A (enExample) |
| KR (1) | KR20050004211A (enExample) |
| CN (1) | CN100408682C (enExample) |
| AR (1) | AR039846A1 (enExample) |
| AU (1) | AU2003240729B2 (enExample) |
| BR (1) | BR0311211A (enExample) |
| CA (1) | CA2485816A1 (enExample) |
| GB (1) | GB0212046D0 (enExample) |
| IL (1) | IL165156A0 (enExample) |
| IS (1) | IS7526A (enExample) |
| MX (1) | MXPA04011527A (enExample) |
| NO (1) | NO20044947L (enExample) |
| NZ (1) | NZ536668A (enExample) |
| PL (1) | PL374569A1 (enExample) |
| RU (1) | RU2303069C2 (enExample) |
| TW (1) | TW200407426A (enExample) |
| WO (1) | WO2003100060A2 (enExample) |
| ZA (1) | ZA200409445B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0212036D0 (en) * | 2002-05-24 | 2002-07-03 | Glaxo Group Ltd | Vaccines |
| GB0304634D0 (en) * | 2003-02-28 | 2003-04-02 | Glaxo Group Ltd | Vaccines |
| GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| ES2476990T3 (es) | 2003-11-12 | 2014-07-15 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sistema para tratar y prevenir cáncer de mama |
| WO2005046622A2 (en) | 2003-11-12 | 2005-05-26 | Therion Biologics Corporation | Custom vectors for treating and preventing pancreatic cancer |
| EP1848804B1 (en) * | 2005-01-28 | 2011-10-05 | Ramot at Tel Aviv University, Ltd. | Anti-muc1 alpha beta antibodies |
| WO2010002478A2 (en) | 2008-07-03 | 2010-01-07 | University Of Georgia Research Foundation, Inc. | Glycopeptide and uses thereof |
| WO2011156751A2 (en) * | 2010-06-11 | 2011-12-15 | University Of Georgia Research Foundation, Inc. | Immunogenic vaccine |
| CN106215179A (zh) * | 2010-06-11 | 2016-12-14 | 乔治亚大学研究基金公司 | 免疫原性疫苗 |
| JP2014518841A (ja) * | 2011-02-24 | 2014-08-07 | オンコシレオン インク． | アジュバントを備えたｍｕｃ１ベースのグリコリポペプチドワクチン |
| CA2954892A1 (en) * | 2016-01-19 | 2017-07-19 | Pfizer Inc. | Immunogens derived from tumor-associated antigens or nucleic acid molecules encoding the immunogens |
| AU2017336269B2 (en) * | 2016-09-28 | 2022-06-16 | Bavarian Nordic A/S | Compositions and methods for enhancing the stability of transgenes in poxviruses |
| EP3794042B1 (en) | 2018-05-18 | 2024-03-27 | Daiichi Sankyo Co., Ltd. | Anti-muc1- exatecan antibody-drug conjugate |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101028523A (zh) * | 1995-11-30 | 2007-09-05 | 德克萨斯州立大学董事会 | 诊断和治疗肿瘤的方法及组合物 |
| CA2282300C (en) * | 1997-02-24 | 2011-08-02 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
| US6228843B1 (en) * | 1999-04-23 | 2001-05-08 | University Technology Corporation | Method of using PKC inhibiting compounds to treat vascular disease |
| WO2001018035A2 (en) * | 1999-09-08 | 2001-03-15 | Transgene S.A. | Muc-1 derived peptides |
| GB9930359D0 (en) * | 1999-12-22 | 2000-02-09 | Glaxo Group Ltd | Novel polypeptides |
| WO2001057068A1 (en) * | 2000-02-01 | 2001-08-09 | The Austin Research Institute | Mucin-1 derived antigens and their use in immunotherapy |
| US20020142047A1 (en) * | 2001-01-19 | 2002-10-03 | Johnson Mark E. | Microsphere delivery of mucin peptides |
| US7125663B2 (en) * | 2001-06-13 | 2006-10-24 | Millenium Pharmaceuticals, Inc. | Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer |
| EP1572918B1 (en) * | 2002-04-15 | 2011-10-19 | Oncothyreon Inc. | Synthetic glyco-lipo-peptides as vaccines |
| GB0212036D0 (en) * | 2002-05-24 | 2002-07-03 | Glaxo Group Ltd | Vaccines |
-
2002
- 2002-05-24 GB GBGB0212046.7A patent/GB0212046D0/en not_active Ceased
-
2003
- 2003-05-22 AR ARP030101782A patent/AR039846A1/es unknown
- 2003-05-22 TW TW092113870A patent/TW200407426A/zh unknown
- 2003-05-23 MX MXPA04011527A patent/MXPA04011527A/es not_active Application Discontinuation
- 2003-05-23 AU AU2003240729A patent/AU2003240729B2/en not_active Ceased
- 2003-05-23 WO PCT/EP2003/005594 patent/WO2003100060A2/en not_active Ceased
- 2003-05-23 NZ NZ536668A patent/NZ536668A/en unknown
- 2003-05-23 PL PL03374569A patent/PL374569A1/xx unknown
- 2003-05-23 CA CA002485816A patent/CA2485816A1/en not_active Abandoned
- 2003-05-23 KR KR10-2004-7018958A patent/KR20050004211A/ko not_active Ceased
- 2003-05-23 US US10/515,871 patent/US20060251665A1/en not_active Abandoned
- 2003-05-23 EP EP03730134A patent/EP1527177A2/en not_active Withdrawn
- 2003-05-23 JP JP2004508299A patent/JP2005526520A/ja active Pending
- 2003-05-23 RU RU2004134331/13A patent/RU2303069C2/ru active
- 2003-05-23 BR BR0311211-0A patent/BR0311211A/pt not_active IP Right Cessation
- 2003-05-23 CN CNB038171988A patent/CN100408682C/zh not_active Expired - Fee Related
-
2004
- 2004-11-10 IL IL16515604A patent/IL165156A0/xx unknown
- 2004-11-11 IS IS7526A patent/IS7526A/is unknown
- 2004-11-12 NO NO20044947A patent/NO20044947L/no not_active Application Discontinuation
- 2004-11-23 ZA ZA200409445A patent/ZA200409445B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005526520A (ja) | 2005-09-08 |
| AU2003240729B2 (en) | 2007-12-20 |
| TW200407426A (en) | 2004-05-16 |
| ZA200409445B (en) | 2006-02-22 |
| KR20050004211A (ko) | 2005-01-12 |
| CA2485816A1 (en) | 2003-12-04 |
| MXPA04011527A (es) | 2005-09-30 |
| NO20044947L (no) | 2005-12-16 |
| RU2303069C2 (ru) | 2007-07-20 |
| CN1668746A (zh) | 2005-09-14 |
| WO2003100060A3 (en) | 2004-02-19 |
| BR0311211A (pt) | 2005-03-01 |
| AU2003240729A1 (en) | 2003-12-12 |
| PL374569A1 (en) | 2005-10-31 |
| IL165156A0 (en) | 2005-12-18 |
| GB0212046D0 (en) | 2002-07-03 |
| NZ536668A (en) | 2007-01-26 |
| IS7526A (is) | 2004-11-11 |
| CN100408682C (zh) | 2008-08-06 |
| NO20044947D0 (no) | 2004-11-12 |
| WO2003100060A2 (en) | 2003-12-04 |
| RU2004134331A (ru) | 2005-08-27 |
| EP1527177A2 (en) | 2005-05-04 |
| US20060251665A1 (en) | 2006-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020009514A (es) | Anticuerpos anti-claudina 18.2 (cldn18.2). | |
| MX2009012650A (es) | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. | |
| ATE510011T1 (de) | Neue pilzproteine und diese codierende nukleinsäuren | |
| MX2010005783A (es) | Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas. | |
| SA522432139B1 (ar) | بروتينات ربط متعددة الخصوصية لمعالجة السرطان | |
| CY1105685T1 (el) | Συνδεομενα με ογκους αντιγονικα παραγωγα απο την οικογενεια mage, και ακολουθιες νουκλεϊκων οξεων που τα κωδικοποιουν, χρησιμοποιουμενα στην παρασκευη πρωτεϊνων συντηξης και συνθεσεων για εμβολιασμο | |
| DE60035337D1 (de) | Humane Peptide/Proteine, die das Töten von Zellen, einschliesslich lymphoide Tumorzellen, herbeiführen oder bewirken | |
| WO2004067706A3 (en) | Production of multimeric proteins | |
| CL2009000648A1 (es) | Propeptido bmp-11 modificado en el residuo 98 de una secuencia bmp-11 humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; metodo para preparar el propeptido, celula recombinante; uso del propeptido para tratar desordenes musculares, neuromusculares, metabolicos, y degenerativos de los huesos (divisional sol.224-02). | |
| AR020601A1 (es) | Peptidos o proteinas de telomerasa para el tratamiento o profilaxis del cancer, composiciones farmaceuticas que incluyen dichos peptidos o proteinas, uso de dicha composicion para la fabricacion de medicamentos y el metodo para generar linfocitos t capaces de reconocer y destruir celulas tumorales c | |
| CL2019003405A1 (es) | Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407) | |
| RU2435851C2 (ru) | Мотивы последовательности рнк в контексте определенных межнуклеотидных связей, индуцирующие специфические иммуномодулирующие профили | |
| WO2023049636A3 (en) | Cancer therapy compositions and uses thereof | |
| DE602004028029D1 (en) | Rwendung | |
| BR0311211A (pt) | Molécula de ácido nucleico codificando um antìgeno de muc-1, plasmìdeo, proteìna, composição farmacêutica, usos de uma molécula de ácido nucleico e de uma proteìna, e, método para tratar ou prevenir tumores ou metástases | |
| ATE520708T1 (de) | Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung | |
| WO2003095480A3 (en) | Brachyspira hyodysenteriae vaccine | |
| DE60125528D1 (de) | Isolierung und charakterisierung des csa-operons (etec-cs4 pili) und verfahren zu dessen anwendung | |
| BR0009775A (pt) | Método para melhorar a migração e invasão de mioblastos no contexto de terapia genética | |
| AR019864A1 (es) | Proceso para producir el antigeno de toxoplasma sag1 o fragmentos del mismo; proteina sag1 o fragmentos de la misma expresada en dicho proceso;composiciones de vacuna que comprendan dicha proteina sag1 o fragmentos de la misma; uso de dicha proteina para la manufactura de medicamentos para preveniry | |
| DE60204317D1 (de) | Methode zur plasmidstabilisierung durch in vivo deletion der antibiotikaresistenz und selektion mit einem essentiellen gen | |
| WO2004007726A3 (en) | Brachyspira hyodysenteriae vaccine | |
| BRPI0407601A (pt) | molécula de ácido nucleico, plasmìdeo, composição farmacêutica, uso de nmolécula de ácido nucleico, e método de tratamento ou de prevenção de tumores | |
| WO2004024769A3 (en) | Ostertagia vaccine | |
| BR0211346A (pt) | Método para produzir um polipeptìdeo, e, precursor de polipeptìdeo para um polipeptìdeo desejado |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |